About Araclon
Araclon is a Healthcare company based in Zaragoza (Spain) founded in 2004, and was acquired by Grifols in March 2012. Develop immunotherapy and diagnostic tests for neurodegenerative disorders. Araclon has raised $11.16 million across 1 funding round from investors including Grifols and Viamed Salud. Araclon offers products and services including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is Araclon Biotech, S.L.
Company details
Araclon Biotech, a spin-off from the University of Zaragoza is dedicated to the research and development of therapies and diagnostic methods for neurodegenerative disorders with the initial focus on Alzheimers disease (AD). It has developed and patented a treatment called ABVac which based on an active immunotherapy (vaccine) for amyloid beta peptides 40 and 42. It has also developed ABtest kit for the early detection of AD by identifying the beta-amyloid 40 and 42 peptides in blood. It is also working on developing a diagnostic test and therapy for Parkinsons disease. In March 2012, Grifols acquired 51 of the capital of Araclon Biotech and since then Araclon is working as its subsidiary.
- Headquarters Zaragoza, Spain
- Stage Acquired
- SectorsHealthcare
- Website araclon.com/en/home
- Social LinkedIn
- Acquired by Grifols (Mar 2012)
- Legal Name Araclon Biotech, S.L.
Products & Services of Araclon
Araclon offers a comprehensive portfolio of products and services, including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40.
Service for early detection of amyloid peptides in plasma samples
Determines total and free Aβ40 and Aβ42 in plasma
Joint determination of Aβ1-40 and Aβ1-42 via mass spectrometry
Active immunotherapy against Aβ40 for Alzheimer's treatment
Funding Insights of Araclon
Araclon has successfully raised a total of $11.16M through 1 strategic funding round. The most recent funding activity was a Series A round of $11.16 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.16M
- Total Rounds 1
- Last Round Series A — $11.16M
- First Round $11.16M
(Jun 2009)
- Investors Count 1
All 1 funding rounds of Araclon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2009 | $11.16M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Araclon
Araclon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Grifols and Viamed Salud.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Hospital and healthcare services are delivered with advanced medical technology. | 2004 | viamedsalud.com | Madrid, Spain | |
Plasma-derived therapies are developed to treat multiple diseases. | 1909 | grifols.com | Barcelona, Spain |
Investor details for Araclon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Araclon
3 dated milestones of Araclon across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Araclon is founded.
- Funding First funding round of $11.2M.
- Exit Acquired by Grifols.
Web traffic of Araclon
The website of Araclon (araclon.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 22.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Araclon
Complete news archive for Araclon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Araclon
Araclon was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Araclon is headquartered in Zaragoza, Spain. It is registered at Zaragoza, Aragon, Spain.
Araclon is a funded company, having raised a total of $11.16M across 1 funding round to date. The company's 1st funding round was a Series A of $11.16M, raised on Jun 2009.
Araclon Biotech, a spin-off from the University of Zaragoza is dedicated to the research and development of therapies and diagnostic methods for neurodegenerative disorders with the initial focus on Alzheimers disease (AD). It has developed and patented a treatment called ABVac which based on an active immunotherapy (vaccine) for amyloid beta peptides 40 and 42. It has also developed ABtest kit for the early detection of AD by identifying the beta-amyloid 40 and 42 peptides in blood. It is also working on developing a diagnostic test and therapy for Parkinsons disease. In March 2012, Grifols acquired 51 of the capital of Araclon Biotech and since then Araclon is working as its subsidiary.
Araclon offers ABtest Service, ABtest-IA, ABtest-MS, and ABvac40.
Araclon has 2 investors. Key investors include Grifols, and Viamed Salud.
Araclon operates through Araclon Biotech, S.L..
Yes. Araclon was acquired by Grifols in March 2012.